Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Breast Cancer Approval Debate Pits Clinical Benefit Versus Statistics

Executive Summary

The Oncology Drugs Advisory Committee's vote against full approval of Roche's Avastin (bevacizumab) for first-line treatment of metastatic breast cancer hinged to a large degree on its feeling that the drug did not delay disease progression long enough to be clinically meaningful
Advertisement

Related Content

FDA “Regulatory Flexibility” On Accelerated Approval Must Result In Some Withdrawals
Quality-Of-Life Data Take On Added Significance With Avastin Debate
Genentech, CDER Tussle Over Avastin Hearing Panel And Format
FDA's Avastin Decision Puts Pressure On Progression-Free Survival Endpoints
Genentech May Not Get A Chance To Appeal FDA's Decision To Withdraw Avastin's Breast Cancer Approval
Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA
Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA
Accelerated Approval: Mend, Don't End, Pazdur Tells ODAC After Avastin
Accelerated Approval: Mend, Don't End, Pazdur Tells ODAC After Avastin
Avastin Bid For Full Approval In Metastatic Breast Cancer May Require Another Trial

Topics

Advertisement
UsernamePublicRestriction

Register

PS052447

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel